Download PDF
Semin intervent Radiol 2008; 25(3): 234-241
DOI: 10.1055/s-0028-1085922
© by Thieme Medical Publishers

Embolotherapy in the Management of Hepatocellular Carcinoma

Alireza Mojtahedi1 , Xiaoming Yang1 , Gaurav K. Goswami1
  • 1Department of Radiology, Section of Interventional Radiology, University of Washington School of Medicine, Seattle, Washington
Further Information

Publication History

Publication Date:
30 September 2008 (online)

Also available at
    Permissions and Reprints

ABSTRACT

Hepatocellular carcinoma (HCC) ranks fifth in frequency of cancers worldwide. The incidence of HCC in the United States is rising, primarily due to the number of patients who were infected by hepatitis in the 1960s and 1970s coupled with the rising migrant population from Asia, where hepatitis is widely prevalent. Up to 80% of the patients present with multicentric HCC and advanced liver disease or comorbidities that restrict the option of resection or liver transplantation. The dual blood supply (arterial and portal) to the liver with predominantly arterial supply to the tumor has made embolotherapy a cornerstone in the management of inoperable HCC. The techniques have become refined not only due to the development of microcatheter angiographic capabilities, but also in the ability to deliver a wide variety of therapeutic agents to these tumors. This article reviews the fundamental principles of bland embolization, chemoembolization, and radioembolization in the management of HCC.

KEYWORDS

Embolization - hepatocellular carcinoma - chemoembolization - radioembolization

REFERENCES

  • 1 Blum H E. Hepatocellular carcinoma: therapy and prevention.  World J Gastroenterol. 2005;  11(47) 7391-7400
    PubMedGoogle Scholar
  • 2 Tanaka Y, Hanada K, Mizokami M et al.. Inaugural Article: A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades.  Proc Natl Acad Sci U S A. 2002;  99(24) 15584-15589
    CrossrefPubMedGoogle Scholar
  • 3 Del Pozo A C, López P. Management of hepatocellular carcinoma.  Clin Liver Dis. 2007;  11(2) 305-321
    CrossrefPubMedGoogle Scholar
  • 4 Befeler A S. Chemoembolization and bland embolization: a critical appraisal.  Clin Liver Dis. 2005;  9(2) 287-300 , vii
    CrossrefPubMedGoogle Scholar
  • 5 Kulik L M. Advancements in hepatocellular carcinoma.  Curr Opin Gastroenterol. 2007;  23(3) 268-274
    PubMedGoogle Scholar
  • 6 Okuda K, Ohtsuki T, Obata H et al.. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients.  Cancer. 1985;  56(4) 918-928
    CrossrefPubMedGoogle Scholar
  • 7 Zhu A X. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.  Cancer. 2008;  112(2) 250-259
    CrossrefPubMedGoogle Scholar
  • 8 Covey A M, Maluccio M A, Schubert J et al.. Particle embolization of recurrent hepatocellular carcinoma after hepatectomy.  Cancer. 2006;  106(10) 2181-2189
    CrossrefPubMedGoogle Scholar
  • 9 Brown K T. Fatal pulmonary complications after arterial embolization with 40–120- micro m tris-acryl gelatin microspheres.  J Vasc Interv Radiol. 2004;  15(2 Pt 1) 197-200
    CrossrefPubMedGoogle Scholar
  • 10 Izaki K, Sugimoto K, Sugimura K, Hirota S. Transcatheter arterial embolization for advanced tumor thrombus with marked arterioportal or arteriovenous shunt complicating hepatocellular carcinoma.  Radiat Med. 2004;  22(3) 155-162
    PubMedGoogle Scholar
  • 11 Lopez P M, Villanueva A, Llovet J M. Systematic review: evidence-based management of hepatocellular carcinoma–an updated analysis of randomized controlled trials.  Aliment Pharmacol Ther. 2006;  23(11) 1535-1547
    CrossrefPubMedGoogle Scholar
  • 12 Cammà C, Schepis F, Orlando A et al.. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.  Radiology. 2002;  224(1) 47-54
    CrossrefPubMedGoogle Scholar
  • 13 Llovet J M, Real M, Montaña X et al.. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.  Lancet. 2002;  359(9319) 1734-1739
    CrossrefPubMedGoogle Scholar
  • 14 Lo C M, Ngan H, Tso W K et al.. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.  Hepatology. 2002;  35(5) 1164-1171
    CrossrefPubMedGoogle Scholar
  • 15 Stuart K. Chemoembolization in the management of liver tumors.  Oncologist. 2003;  8(5) 425-437
    CrossrefPubMedGoogle Scholar
  • 16 Ensminger W D, Gyves J W. Clinical pharmacology of hepatic arterial chemotherapy.  Semin Oncol. 1983;  10(2) 176-182
    PubMedGoogle Scholar
  • 17 Lewis A L, Gonzalez M V, Lloyd A W et al.. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization.  J Vasc Interv Radiol. 2006;  17(2 Pt 1) 335-342
    CrossrefPubMedGoogle Scholar
  • 18 Qian J, Truebenbach J, Graepler F et al.. Application of poly-lactide-co-glycolide-microspheres in the transarterial chemoembolization in an animal model of hepatocellular carcinoma.  World J Gastroenterol. 2003;  9(1) 94-98
    PubMedGoogle Scholar
  • 19 Poon R T, Tso W K, Pang R W et al.. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead.  Clin Gastroenterol Hepatol. 2007;  5(9) 1100-1108
    CrossrefPubMedGoogle Scholar
  • 20 Constantin M, Fundueanu G, Bortolotti F et al.. Preparation and characterisation of poly(vinyl alcohol)/cyclodextrin microspheres as matrix for inclusion and separation of drugs.  Int J Pharm. 2004;  285(1–2) 87-96
    CrossrefPubMedGoogle Scholar
  • 21 Murthy R, Nunez R, Szklaruk J et al.. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications.  Radiographics. 2005;  25(Suppl 1) S41-S55
    CrossrefPubMedGoogle Scholar
  • 22 Kennedy A, Nag S, Salem R et al.. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium.  Int J Radiat Oncol Biol Phys. 2007;  68(1) 13-23
    CrossrefPubMedGoogle Scholar
  • 23 Kulik L M, Atassi B, van Holsbeeck L et al.. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation.  J Surg Oncol. 2006;  94(7) 572-586
    CrossrefPubMedGoogle Scholar
  • 24 Sangro B, Bilbao J I, Boan J et al.. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma.  Int J Radiat Oncol Biol Phys. 2006;  66(3) 792-800
    CrossrefPubMedGoogle Scholar
  • 25 Ibrahim S M, Lewandowski R J, Sato K T et al.. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review.  World J Gastroenterol. 2008;  14(11) 1664-1669
    CrossrefPubMedGoogle Scholar

Gaurav K GoswamiM.D. 

University of Washington Medical Center

1959 NE Pacific St, Seattle, WA 98195

Email: goswamig@u.washington.edu

      >